

Supplemental Figure 1: Dot plots of liver and lymph node NK cell subsets

Supplemental Figure 2: Breakdown of NK cell subsets

(A) Expression of Ly49G2 and Ly49A on unlicensed (Ly49C/I-) NK cells in lymph nodes (LN) on dpi 5

(B) Expression of Ly49G2 and Ly49A on unlicensed (Ly49C/I-) NK cells in liver on dpi 5

(C) Ly49H expression on licensed and unlicensed NK cells in the liver on dpi 5

Supplemental Figure 3: Subset depletion validation

Populations of splenic CD3-NK1.1 NK cells expressing either Ly49I (clone YLI-90), Ly49G2 (clone Cwy3) or Ly49A (clone YE1/48.10.6) following in vivo depletion with anti-Ly49C/I (clone 5E6; licensed), anti-Ly49G2 (clone 4D11; unlicensed) or anti-Ly49A (clone YE1/32; unlicensed). Depletion was verified 7 days following administration of antibody and compared with isotype control treated animals.

Supplemental Figure 4: Linear regression of MCMV-specific tetramer+ T cells and viral titers

(A) Low dose infection tetramer+ T cell numbers and viral titers

(B) High dose infection tetramer+ T cell numbers and viral titers

Supplemental Figure 5: The effect of NK cell subset depletion on MCMV-specific tetramer+ T cells across organs

(A) Spleen on day 7 post-infection



(B) Lymph nodes (LN) on day 7 post-infection

Supplemental Figure 6: Frequency of Ly49H on licensed and unlicensed NK cells on day 7 post-infection in control and HSCT mice



Liver

Lymph Nodes



Uninfected







Low Dose




High Dose






A**B****C**



Supplemental Figure 3

A**B**

A**B**



Supplemental Figure 6